POSTER: ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine with Rituximab (Lonca-R) Versus Immunochemotherapy in Patients with R/R DLBCL
Clinical Lymphoma Myeloma & Leukemia（2023）
关键词
aggressive B-cell lymphoma (ABCL),B cell,non-Hodgkin lymphoma,loncastuximab tesirine,rituximab,phase III
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要